Insilico Medicine

Insilico Medicine is an AI-driven drug-discovery company building generative AI tools and using them to discover novel therapeutics. Founded in 2014 by Alex Zhavoronkov, the company has raised over $400 million across multiple funding rounds led by Warburg Pincus, Qiming Venture Partners, B Capital, and Sequoia Capital China. Insilico operates from dual headquarters in New York City and Hong Kong, with research operations in Cambridge MA, the UAE, and mainland China.

The Pharma.AI suite is the company's core technology platform, comprising three integrated AI systems: PandaOmics (multi-omic target identification using ML over disease-relevance data), Chemistry42 (generative chemistry — generating novel drug-like molecules optimized for binding affinity, solubility, toxicity, and synthesizability), and InClinico (predicting Phase II clinical-trial success probability from preclinical data). The platform has been licensed to over a dozen major pharmaceutical companies (Sanofi, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, etc.) for collaborative drug-discovery programs.

Insilico's lead internal asset is INS018_055, a small-molecule inhibitor targeting idiopathic pulmonary fibrosis (IPF). The drug entered Phase I trials in 2023 and Phase II in late 2023 — the world's first wholly AI-discovered, AI-designed drug to reach Phase II clinical trials. Additional AI-discovered candidates target diseases including ulcerative colitis, COVID-19 sequelae, and various oncology indications. The company's broader pipeline includes more than 30 active programs, with the strategic vision of compressing the typical 4.5-year preclinical-to-IND timeline to under 18 months. Insilico has IPO'd on the Hong Kong Stock Exchange (filed in 2023) and is one of the most-watched AI-drug-discovery companies globally.